Galantamine (reminyl) in the treatment of Alzheimer's disease and vascular dementia

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 103, Issue 12, 2003, Pages 59-65

  Gavrilova, S I ^a   Zharikov, G A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG COMBINATION; HUMAN; MULTIINFARCT DEMENTIA; REVIEW; TREATMENT OUTCOME;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; DEMENTIA, VASCULAR; DRUG THERAPY, COMBINATION; GALANTAMINE; HUMANS; TREATMENT OUTCOME;

EID: 3843093012     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Bartus R.T.,Dean R.L.,Beer B.,Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-417.
2. Blesa R., Davidson M., KurzA. et al. Galantamine provides sustained benefits in patients with Advanced moderate Alzheimer's disease for at least 12 months. Dement Geriat Coan Disord 2003; 15: 79-87.
3. Bullock R., Lilienfeld S. Galantamine shows promising results in probable vascular dementia and Alzheimer's disease with cerebrovascular components. Poster presented at. XVII World Congress of Neurology. London UK 2001.
4. Chui H., Gonthicr R. Natural history of vascular dementia. Alzheimer Dis Assoc Disord 1999; 13: Suppl 3: 24-30.
5. Davies P., Moloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403-1404.
6. Davis K.L., Mohs R.C., Marin D. el al. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA 1999; 281: 1401-1406.
7. Dib M. Methodological issues and therapeutic perspectives in vascular dementia: a review. Arch Gerontol Geriat 2001; 33: 71-80.
8. Erkinjuntti T. Cognitive decline and treatment options for patients with vascular dementia. Acta Neurol Scand 2002; 106: Suppl 178: 15-18.
9. Erkinjuntti T., KurzA., GauthierS. et al. Galantamine is efficacious in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Lancet 2002; 359: 1283-1290.
10. Erkinjuntti T, Lilienfeld S. Galantamine is safe and effective over 24 months in patients with probable vascular dementia: an interim analysis. Poster presented at the 18"1 Annual Conference of Alzheimer's Disease International. Barcelona, Spain 23-26 October 2002.
11. Ernst R.L., Hay J. IV. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994; 84: 1261-1264.
12. Feldman H., SaitterA., Donald A. et al.The Disability Assessment for Dementia scale: A 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 2001; 15: 89-95.
13. Ferrari R., Frasoldati A., Leo G. el al. Changes in nicotinic acetylcholine receptor subunit mRNAs and nicotinic binding in spontaneously hypertensive stroke prone rats. Neurosci Lett 1999; 277: 169-172.
14. Ferris S.H., RaskindM.A., Mehnerl A., MintzerJ.E. Cognitive decline in untreated patients with Alzheimer's disease. Poster presented at the XVII World conaress of Neuroloay. London UK 17-22 June 2001.
15. Forette F., Boiler F. Drug development in Alzheimer's Disease. In: S. Gauthier (eds.). London: Martin Dunitz 1988; 1-15.
16. Forette F., Seux M.L., Staessen J.A. et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-1351.
17. Gelinas I., Gauthier L., Mclntyre M., Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471-481.
18. Gotlfries C.G., Blennow K., Karlsson I., Wallin A. The neurochemistry of vascular dementia. Dementia 1994; 5: 163-167.
19. Kalaria R.N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000; 57: 1295-1300.
20. Kimura S., Saito II., Minami M. et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicoloay 2000; 153: 167-178.
21. Kumar V., Anand R., Messina J. et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159-169.
22. Kunik M.E., Huffman J.C., Bharani N. et al. Behavorial disturbances in geropsychiatric inpatients across dementia types. J Geriat Psychiat Neurol 2000; 13: 49-52.
23. Kurz A. Non-cognitive benefits of galantamine (Reminyl) treatment in vascular dementia. Acta Neurol Scand 2002; 106: Suppl 178: 19-24.
24. Lang dir. J.G., Heiler-Reiffensluhl L, Schwalen S. Galantamine, a novel drug with unique dual mode of action reduces depression in Alzheimer's disease. Poster presented at the 6'" Congress of the European federation of Neurological Societies. Vienna 2002.
25. Lehfeld H., Reisberg B., Finkel S. et al. Informant-rated activities-of-daily-living (ADL) assessments: results of a study of 141 items in the USA, Germany, Russia, and Greece for the International ADL Scale Development Project. Alzheimer Dis Assoc Disord 1997; 11: S39-44.
26. Lyketsos C.G., Steinberg M., TschanzJ.T. et al. Mental and behavorial disturbances in dementia: findings from the Cache county study on memory and aging. Am J Psychiat 2000; 157: 708-714.
27. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2000; 11: Suppl: 11-18.
28. Maelicke A., Albuquerque E.X. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strateey for Alzheimer's disease. Eur J Pharmacol 2000; 393: 165-170.
29. Maelicke A. The pharmacological rationale for treating vascular dementia with galantamine (reminyl). Int J Clin Pract 2001; 120: Suppl: 24-28.
30. McKhann G., Drachman D., Folstein 1. et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 146: 939-944.
31. Mendez M.F., Younesi P.L., Ferryman K.M. Use of donepezil for vascular dementia: preliminary clinical experience. J Neuropsychiat Clin Neurosci 1999; 11: 268-270.
32. Moretti R., Torre P., Antonello R.M., Cazzato G. Rivastigmine in subcortical vascular dementia, a comparison trial on efficacy and toler-ability for 12 months follow-up. Eur J Neurol 2001; 8: 361-362.
33. National Institute for Clinical Exellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. Technology Appraisal Guidance 2001; 19.
34. Olin J., Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). Cochrane Library, issue 2. Oxford: Update Software 2001.
35. Raskind M.A., Peskind E.R., Wessel T, Yuan W. On behalf of the Galantamine USA-1 Study Group: Galantamine in AD: A 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-2268.
36. Rocca W.A., Hofman A., Brayne C. et al. The prevalence of vascular dementia in Europe: facts and fragments from 1980-1990 studies. Ann Neurol 1991; 30: 817-824.
37. Rockwood K., Ebly E., Hachinski V., Hogan D. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurol 1997; 54: 33-39.
38. Roman G.C., Tatemichi T.K., Erkinjuntti T. et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIR-EN International Workshop. Neurology 1993; 43: 250-260.
39. Saito H., Togashi H., Yoshoka M. et al. Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppi 1995; 1: S257-S259.
40. Schneider L.S. New therapeutic approaches to Alzheimer's disease. J Clin Psychiat 1996; 57: Suppl 14: 30-36.
41. Shaw W.S.elal. Longitudinal analysis of multiple indicatorsof health decline among spousal caregivers. Ann Behav Med 1997; 19: 101-109.
42. Shulz R., Beach S.R. Caregiving as a risk factor for mortality. JAMA 1999; 23: 2215-2219.
43. Skoog I. The interaction between vascular disorders and Alzheimer's disease. In: Alzheimer's disease and related disorders. Etiology, Pathogenesis and Therapeutics. K. Iqbal, D.F. Swaab, B. Winblad, H.M. Wisniewski (eds.). John Wiley & Sons Ltd 1999; 523-530.
44. Small G.W., LilienfeldS. Galantamine demonstrates overall efficacy regardless of baseline disease severity in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. Poster presented at the 127 Annual Meeting of the America Neurological Association. New York 2002.
45. Tariot P.N., Solomon P.R., Morris J.C. et al. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's Disease. Neurology 2000; 54: 2269-2276.
46. Togashi H., Matsumoto M., Yoshioka M. et al. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci Lett 1994; 166:117-120.
47. Wessel T, Gaens E. The long-term cognitive benefits of galantamine treatment in patients with Alzheimer's disease (poster), 125th Annu Meet. Am Neurol Assoc. Boston 2000.
48. Wilcock G.K., Lilienfeld S. Galantamine alleviates caregivers burden in Alzheimer's disease: a 6 months placebo-controlled study. 7,h International World Alzheimer's Congress. Washington D.C., USA 2000.
49. Wilcock G.K., Lilienfeld S., Gaens E. On behalf of the Galantamine International-1 Study Group: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: A multicentre randomised controlled trial. BMJ 2000; 321: 1445-1449.
50. Wilkinson D.G., Truyen L. Prolonged treatment benefits of cholinergic agents in Alzheimer's disease Poster presentation at the XVlIth World Congress of Neurology. London UK 17-22 June 2001.
51. Wilkinson D.G., Hock C., Farlow M. et al. Galantamine provides broad benefits in patients with advanced moderate Alzheimer's disease (MMSE